APYX Stock Forecast & Price Target

Apyx Medical Corp is demonstrating strong financial momentum, with Surgical Aesthetics revenue projected to reach between $43 million and $45 million, representing a 14% year-over-year increase at the midpoint. The company has revised its full-year revenue guidance upward to a range of $50.5 million to $52.5 million, primarily driven by enhanced execution and increasing demand in the Surgical Aesthetics segment. This growth is further supported by the successful commercial launch of the AYON Body Contouring System, contributing to a reported 12% increase in total revenue, which exceeded market expectations.

Apyx Medical Corp has experienced a decline in expectations for its OEM sales, with management projecting ~$7.5 million, down from previous guidance of ~$8.0 million, largely due to reduced sales volumes from specific customers. The company continues to grapple with the negative repercussions of an FDA warning letter from March 2022, compounded by an increase in GLP-1 usage that poses further challenges. Additionally, the decline in cash and cash equivalents, from $29.3 million to $25.1 million in the third quarter of 2025, alongside potential regulatory setbacks and macroeconomic pressures, contributes to a negative outlook on the stock.